HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: Children’s Motrin Trial Verdict, Gag’s Up For Roca Labs

This article was originally published in The Tan Sheet

Executive Summary

Jury finds J&J/McNeil not liable to warn on Children’s Motrin labels about a risk of severe skin conditions; gag’s up for Roca Labs; Omega Protein could be available; and more news in brief.

You may also be interested in...



FTC Settles Big With Sensa, Other Weight-Loss Marketers

FTC settles with Sensa products and three other weight-loss product marketers, and launches its “gut check” voluntary media partnership program to prevent bogus claims. A firm cited in FTC’s 2011 investigation of human chorionic gonadotropin product ads also reached a settlement with the agency.

‘A Global Movement For More Democracy In Medicine’ – Formycon Chief Talks Biosimilars Strategy

Characterizing biosimilars as a global movement towards the democratization of medicine, Formycon CEO Stefan Glombitza speaks to Generics Bulletin in detail about the company’s recent deals, launches and key pipeline assets, in the first part of an exclusive two-part interview.

UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024

Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel